Summary: Metered Dose Inhalers (MDIs) are widely used in the treatment and management of respiratory conditions such as ...

AstraZeneca and GlaxoSmithKline have long locked horns in their battle for respiratory supremacy with the latter holding the clear advantage in triple-drug inhaler market. Can another round of ...

Human Respiratory Syncytial Virus Drugs Dominated by Synagis, the only Approved Drug in the Market: Technavio Technavio publishes a new market research report on the global human respiratory syncytial ...

An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could ...

As face masks, hand sanitizers and rubber gloves fly off store shelves, pharmacists are quietly fretting over a looming shortage of vital prescription medications. On Thursday pharmaceutical ...

The new monoclonal antibody treatment defends against serious, potentially life-threatening disease in infants and vulnerable children up to age 2. The U.S. Food and Drug Administration (FDA) on ...

GlaxoSmithKline has terminated (PDF) 11 projects over the past 12 months. The respiratory franchise bore the brunt of the cuts at a time when some GSK staff were questioning the wisdom of investing in ...

Fosun Pharma's subsidiary, Fosun Pharma Industrial, has entered a licence agreement to grant ex-China rights for its experimental respiratory drug, XH-S004, to Expedition Therapeutics. This agreement ...

LONDON (Reuters) - AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product ...